Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Heartflow, Inc. Common Stock

HTFL

HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

Last trade $46.99
Day change +$0.13 (+0.28%)
Day range $45.65 – $48.05
Volume 741,399
Market cap $4.12B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.12B
Price / earnings
—
Price / book
14.58×
Price / sales
17.26×
EV / sales
17.12×
EV / EBITDA
-61.81×

Profitability

Earnings per share
-$0.90
Return on assets
-22.24%
Return on equity
-27.97%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.41×
Quick ratio
4.41×
Cash ratio
0.59×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$56.07M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HTFL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025
Revenue$72.86M$64.08M$52.59M$49.13M$46.28M
Cost of revenue$11.94M$10.89M$10.42M$10.07M$10.86M
Gross profit$60.92M$53.19M$42.16M$39.06M$35.42M
Selling, general and administrative$45.28M$44.83M$42.57M$38.15M$33.22M
Research and development$29.49M$26.26M$21.62M$18.67M$17.3M
Total operating expenses$74.76M$71.09M$71.67M$56.81M$50.51M
Operating income-$13.85M-$17.9M-$29.5M-$17.75M-$15.1M
Interest expense-$5K$0-$3K-$8K-$3.45M
Income before taxes-$11.48M-$15.72M-$27.36M-$24.56M-$50.83M
Income taxes$23K$22K$23K-$165K$30K
Net income-$11.51M-$15.74M-$27.38M-$24.4M-$50.86M
Net income attributable to common shareholders-$11.51M-$15.74M-$27.38M-$24.4M-$50.86M
EBITDA-$12.46M-$16.68M-$20.6M-$16.38M-$13.8M
Basic earnings per share-$0.13-$0.18-$0.32-$0.28-$1.04
Diluted earnings per share-$0.13-$0.18-$0.32-$0.28-$1.04

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow raised its full-year 2026 revenue guidance to $262-264 million, with Q3 revenue growing 57% year-over-year. The company's Plaque Analysis software demonstrated a 34% reduction in major cardiovascular events in clinical trials, accelerating hospital adoption. Management initiated clinical trials targeting asymptomatic patients to expand the addressable market by $6 billion to $11 billion total, with expectations to achieve cash flow profitability by mid-2028.

Zacks Investment Research

HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates

HeartFlow (HTFL) reported a quarterly loss of $0.03 per share, beating consensus estimates of $0.10 loss, with a 70% earnings surprise. Revenue of $72.86 million exceeded expectations by 11.92%. The stock has gained 102.7% year-to-date but received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

iRhythm Holdings, Inc. (IRTC) Q3 Earnings Surpass Estimates

iRhythm Holdings (IRTC) reported Q3 2026 earnings of $0.82 per share, significantly beating the consensus estimate of $0.02, representing a 4,000% surprise. However, revenues of $221.59 million slightly missed expectations by 0.31%. Despite the earnings beat, the stock has underperformed the market by 24.5% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends.

GlobeNewswire Inc.

TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients

Heartflow announced landmark clinical data from the P4 randomized trial showing CT-guided PCI planning matches gold-standard IVUS outcomes for one-year clinical results while reducing procedure time by 27% and contrast volume by 12%. The NAVIGATE-PCI registry demonstrated that Heartflow PCI Navigator modified treatment plans in approximately 70% of patients, primarily affecting stent length and lesion preparation decisions.

Zacks Investment Research

Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) reported a quarterly loss of $0.19 per share, beating the consensus estimate of $0.26 loss and representing a 26.92% earnings surprise. The company posted revenues of $22.84 million, surpassing consensus by 3.75%. However, shares have underperformed the market, down 11.8% year-to-date versus the S&P 500's 12.1% gain. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.